GoodRx announced a collaboration with ARS Pharmaceuticals, Inc. to offer the lowest discounted cash price for neffy®, an epinephrine nasal spray, at retail pharmacy locations. This needle-free treatment for Type I allergic reactions, including anaphylaxis, was approved by the Food and Drug Administration in August.
Consumers who have been prescribed neffy can now access a pack of two single-use devices for $199 exclusively through GoodRx at over 70,000 pharmacies nationwide. This initiative aims to break down barriers in anaphylaxis treatment by enhancing accessibility and affordability for millions of Americans.
The partnership highlights GoodRx's commitment to championing innovation and making essential medications more accessible. It also expands the company's portfolio of direct savings programs with pharmaceutical manufacturers, which currently includes nearly 150 brands.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.